Okada Taiji, Hyakudomi Miki, Yamaguchi Kazuto, Watanabe Nobuhide, Endo Akihiro, Yoshitomi Hiroyuki, Tanabe Kazuaki
Division of Cardiology, National Hospital Organization Hamada Medical Center, 777-12 Asaichō, Hamada, Shimane 697-8511 Japan.
Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Hamada, Shimane Japan.
Int Cancer Conf J. 2020 Jun 22;9(4):207-211. doi: 10.1007/s13691-020-00427-1. eCollection 2020 Oct.
The dose-dense epirubicin and cyclophosphamide (EC) therapy for breast cancer decreases the risk of cancer recurrence and death. However, epirubicin and cyclophosphamide also cause cardiotoxicity, and cardiomyopathy is the most well-known related adverse effect. A 58-year-old woman presented to our hospital with palpitations 2 weeks after her final dose-dense EC therapy for breast cancer. Holter electrocardiogram (ECG) showed transitory complete atrioventricular block (CAVB) and torsade de pointes. A 12-lead ECG showed QT prolongation in addition to CAVB. Patients receiving dose-dense EC therapy should be monitored more carefully with ECG due to their risk of fatal arrhythmias.
密集剂量表柔比星联合环磷酰胺（EC）治疗乳腺癌可降低癌症复发和死亡风险。然而，表柔比星和环磷酰胺也会引起心脏毒性，心肌病是最广为人知的相关不良反应。一名58岁女性在完成乳腺癌密集剂量EC治疗2周后因心悸前来我院就诊。动态心电图显示短暂性完全性房室传导阻滞（CAVB）和尖端扭转型室速。12导联心电图显示除CAVB外还有QT间期延长。由于接受密集剂量EC治疗的患者有发生致命性心律失常的风险，因此应通过心电图对其进行更密切的监测。
